Tirzepatide expanded the field from one receptor (GLP-1) to two (GLP-1 + GIP)
It is a glucagon-like peptide-1 (GLP-1) receptor agonist
There are other forms of bias in these datasets including channeling (e.g., the prescribing pattern depends on a patient characteristic (particularly diabetes or obesity) that is a PDAC risk factor), detection (e.g., overreporting due to additional testing to rule out a suspected adverse event (e.g., imaging triggered by pancreas enzyme elevations)), and Weber effect (initial increase in event reporting shortly after drug launch) 49
Many global consumers are unaware of its health benefits, traditional uses, or preparation methods
However, this participant had a slower dose titration due to their heart failure, so took longer to reach the maximum dose
Timelines differ by person, dose, and medication, and clinical trials titrate doses gradually over months